News >

Immunotherapy Combos May Have Role in Ovarian Cancer

Caroline Seymour
Published: Wednesday, Jan 23, 2019

Panagiotis A. Konstantinopoulos, MD, PhD

Panagiotis A. Konstantinopoulos, MD, PhD
The use of immunotherapy agents in patients with ovarian cancer has proven to be challenging, explained Panagiotis A. Konstantinopoulos, MD. Amid modest responses, as well as a recent negative phase III trial, the future role of this approach in the space remains unclear.

For example, in November 2018, Merck KGaA and Pfizer, the developers of avelumab (Bavencio), announced that the PD-L1 inhibitor alone and in combination with pegylated liposomal doxorubicin (PLD) failed to demonstrate a statistically significant improvement in progression-free survival (PFS) and overall survival (OS) over PLD alone in patients with platinum-resistant/-refractory ovarian cancer in the phase III JAVELIN Ovarian 200 trial.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication